Role of STAT5 and Bcl-xL in human B cell survival

Information

  • Research Project
  • 6998769
  • ApplicationId
    6998769
  • Core Project Number
    F32AI063846
  • Full Project Number
    1F32AI063846-01A1
  • Serial Number
    63846
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/2005 - 19 years ago
  • Project End Date
    8/31/2008 - 16 years ago
  • Program Officer Name
    FABIAN, MILES
  • Budget Start Date
    9/1/2005 - 19 years ago
  • Budget End Date
    8/31/2006 - 18 years ago
  • Fiscal Year
    2005
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    7/27/2005 - 19 years ago
Organizations

Role of STAT5 and Bcl-xL in human B cell survival

[unreadable] DESCRIPTION (provided by applicant): Interleukin (IL)-2 and IL-4 are important for the growth of human primary B cells. These cytokines activate signal transducer and activator of transcription (STAT) 5. However, the role of STAT5 in normal human B cell growth is not completely clear. Our preliminary data suggest that activation of STAT5 promotes survival of normal human B cells. STAT5 is known to regulate expression of anti-apoptotic Bcl-xL. We, therefore, propose that STAT5 prevents normal B cell apoptosis through upregulation of Bcl-xL. In the first aim of this proposal we will investigate whether STAT5 supports B cell growth through inhibition of apoptosis by using overexpression and RNA interference approaches. In the second aim of this proposal we will investigate whether STAT5 can regulate B cell apoptosis through upregulation of Bcl-xL and we will determine the requirement for Bcl-xL in STAT5-mediated protection from apoptosis. Lastly we will identify new STAT5-regulated anti-apoptotic genes in addition Bcl-xL through RT-MLPA, a novel gene expression analysis method. Findings from this proposal will provide insight into the control of normal human B cell growth and may provide new targets for treatment of B cell malignancies. [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    F32
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    41796
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:41796\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIVERSITY OF AMSTERDAM
  • Organization Department
  • Organization DUNS
  • Organization City
    AMSTERDAM
  • Organization State
  • Organization Country
    NETHERLANDS
  • Organization Zip Code
  • Organization District
    NETHERLANDS